Adalimumab for moderate to severe chronic plaque psoriasis: efficacy and safety of retreatment and disease recurrence following withdrawal from therapy
Author:
Publisher
Wiley
Subject
Dermatology
Link
http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1365-2133.2010.10139.x/fullpdf
Reference14 articles.
1. Benefit-risk assessment of tumour necrosis factor antagonists in the treatment of psoriasis;Langley;Br J Dermatol,2010
2. Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial;Menter;J Am Acad Dermatol,2008
3. CHAMPION Study Investigators. Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION);Saurat;Br J Dermatol,2008
4. Efficacy and safety of adalimumab treatment in patients with moderate to severe psoriasis: a double-blind, randomized clinical trial;Gordon;Psoriasis Forum,2007
5. Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomised controlled trial and open-label extension study;Gordon;J Am Acad Dermatol,2006
Cited by 101 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Formation and clinical effects of anti-drug antibodies against biologics in psoriasis treatment: An analysis of current evidence;Autoimmunity Reviews;2024-04
2. Can Biologics Be Discontinued in Patients with Psoriatic Arthritis in Stable Remission? A Prospective Single-CenterClinical and Ultrasound Study;Dermatologic Therapy;2023-11-04
3. New findings of macrophages in initiating and sustaining psoriasis;2023-07-11
4. Spesolimab improves patient‐reported outcomes in patients with generalized pustular psoriasis: Results from the Effisayil 1 study;Journal of the European Academy of Dermatology and Venereology;2023-01-23
5. Efficacy, Safety, and Pharmacoeconomic Analysis of Adalimumab and Secukinumab for Moderate-to-Severe Plaque Psoriasis: A Single-Center, Real-World Study;Dermatology and Therapy;2022-08-11
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3